Home / Biz updates
HTA Co and Beijing Datsing Bio-Tech Co, two Beijing-based enterprises in Zhongguancun’s core area, have joined the city’s bio-pharmaceutical industry development projects (G20 Project), according to the Zhongguancun administrative committee.
HTA Co is a high-tech enterprise founded by the China Institute of Atomic Energy with net assets exceeding 100 million yuan ($16.1 million). In 2006, the company successfully listed in the New Third Board, a national share transfer system for small and medium-sized enterprises to transfer shares and raise funds, or seek IPOs overseas. It also has the largest production and R&D base for radioactive isotope products in China.
The other enterprise, Beijing Datsing Bio-Tech Co, has core technology platforms for biomedical materials, stem cells, biological treatment, regenerative medicine and tissue engineering. It has made a number of breakthroughs in technology industrialization by absorbing advanced technology and resources from China and overseas.
In addition, the company possesses six national invention patents and several international leading proprietary technologies. It has modern workshops and laboratories covering a total area of 2,500 square meters.
